98 results
8-K
EX-3.1
FGEN
FibroGen Inc
21 Nov 14
Material Modifications to Rights of Security Holders
12:00am
then outstanding) by the affirmative vote of the holders of a majority of the voting power of the stock of the Company entitled to vote thereon, without … that shall constitute the Board of Directors shall be fixed exclusively by resolutions adopted by a majority of the authorized number of directors
S-1
EX-3.2
FGEN
FibroGen Inc
1 Oct 14
IPO registration
12:00am
, the presence, in person or represented by proxy, of the holders of a majority of the aggregate voting power of the stock issued and outstanding, entitled … to vote thereat, shall constitute a quorum for the transaction of business at all meetings of the stockholders. If such majority shall not be present
CORRESP
14t2j8e6
31 Jan 20
Correspondence with SEC
12:00am
S-3ASR
EX-4.5
0bu5fqf6 c4f7490uckq
2 Mar 20
Automatic shelf registration
5:30pm
8-K
EX-99.1
vgvxxhnd1
28 Jun 19
Regulation FD Disclosure
9:01am
S-1
EX-4.4
xka 0d8doj
1 Oct 14
IPO registration
12:00am
S-1
EX-4.15
4l7id27
1 Oct 14
IPO registration
12:00am
CORRESP
s6rkuoim2o5eeoe3ltd
13 Dec 19
Correspondence with SEC
12:00am
S-1
EX-4.8
crtilv
1 Oct 14
IPO registration
12:00am
CORRESP
74j1n7mywi0vxybs
21 Feb 20
Correspondence with SEC
12:00am
8-K
EX-99.1
a261o zakjen4ijv
15 Apr 19
Other Events
9:00am
S-1
EX-4.9
sg3dru uyz9r3od50a7
1 Oct 14
IPO registration
12:00am
8-K
EX-99.1
ph4 ee5it3
26 Jun 23
FibroGen Announces Topline Results from Phase 3 ZEPHYRUS-1 Study of Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis
9:05am
8-K
citcepuu
19 Jul 23
Cost Associated with Exit or Disposal Activities
7:01am
8-K
EX-99.1
ekwrok1hf
7 Jun 23
FibroGen Announces Topline Results from LELANTOS-1 Phase 3 Clinical Study of Pamrevlumab in Non-Ambulatory Patients with Duchenne Muscular Dystrophy
9:00am